A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: Data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden Academic Article uri icon

Overview

MeSH Major

  • Mass Screening
  • Prostate-Specific Antigen
  • Prostatic Neoplasms

abstract

  • Multiple kallikrein forms measured in blood can predict the result of biopsy in previously unscreened men with elevated PSA. A multivariable model can determine which men should be advised to undergo biopsy and which might be advised to continue screening, but defer biopsy until there was stronger evidence of malignancy.

publication date

  • July 8, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2474851

Digital Object Identifier (DOI)

  • 10.1186/1741-7015-6-19

PubMed ID

  • 18611265

Additional Document Info

start page

  • 19

volume

  • 6